Hostname: page-component-6587cd75c8-cpvbf Total loading time: 0 Render date: 2025-04-24T03:45:16.093Z Has data issue: false hasContentIssue false
  • English
  • Français

Aiming at the Right Targets on Drug Price Reform

Published online by Cambridge University Press:  04 March 2024

Stacie B. Dusetzina Open the ORCID record for Stacie B. Dusetzina [Opens in a new window]
Get access Rights & Permissions [Opens in a new window]

Abstract

A lack of transparency and concerns over patients costs at the pharmacy counter have increased Congressional focus on pharmacy benefits management practices. However, applying regulations without transparency into pharmacy benefits managers practices could do more harm than good.

Keywords

Pharmacy Benefits ManagersPrice TransparencyDrug Rebates
Type
Commentary
Information
Journal of Law, Medicine & Ethics , Volume 51 , Issue S2: Promoting Drug and Vaccine Innovation and Managing High Prices: Three Proposals for Policy Reform , Winter 2023 , pp. 55 - 57
Copyright
© 2023 The Author(s)

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

What Medicare Part D Drug Plans Cover (2023), Medicare.gov, available at <https://www.medicare.gov/drug-coverage-part-d/what-medicare-part-d-drug-plans-cover> (last visited August 28, 2023).+(last+visited+August+28,+2023).>Google Scholar
Sachs, R., Trump Administration Releases Long-Awaited Drug Rebate Proposal (February 1, 2019), Health Affairs Blog, available at <https://www.healthaffairs.org/content/forefront/trump-administration-releases-long-awaited-drug-rebate-proposal> (last visited August 28, 2023).+(last+visited+August+28,+2023).>Google Scholar
Rowland, C., Drug Executives Grilled in Senate over High Prices (February 26, 2019), Washington Post, available at <https://www.washingtonpost.com/business/economy/drug-executives-grilled-in-senate-over-high-prices/2019/02/25/abc89c04-393f-11e9-aaae-69364b2ed137_story.html> (last visited August 28, 2023).+(last+visited+August+28,+2023).>Google Scholar
Incorporating the Effects of the Proposed Rule on Safe Harbors for Pharmaceutical Rebates in CBO’s Budget Projections—Supplemental Material for Updated Budget Projections: 2019 to 2029 (May 2019), Congressional Budget Office, available at <https://www.cbo.gov/system/files/2019-05/55151-SupplementalMaterial.pdf> (last visited August 28, 2023).+(last+visited+August+28,+2023).>Google Scholar
Herman, B., CVS Warns PBM Reforms “Could Lead to Higher Costs” (May 31, 2023), STAT, available at <https://www.statnews.com/2023/05/31/cvs-pbm-reforms-rebates-spread-pricing/> (last visited August 28, 2023).+(last+visited+August+28,+2023).>Google Scholar
See Examining Policies That Inhibit Innovation and Patient Access: Hearing before the House Ways and Means Subcommittee on Health, 118th Cong., (2023) (testimony of Benjamin N. Rome, M.D., M.P.H.) available at <https://waysandmeans.house.gov/wp-content/uploads/2023/05/Rome-Testimony.pdf> (last visited November 27, 2023).+(last+visited+November+27,+2023).>Google Scholar
Slifer, E. and Llamas, A., Bipartisan Congressional Support for PBM Reform Grows (June 21, 2023), The Commonwealth Fund, available at <https://www.commonwealthfund.org/blog/2023/bipartisan-congressional-support-pbm-reform-grows> (last visited August 28, 2023).+(last+visited+August+28,+2023).>Google Scholar
Wyden, Senator Ron, Wyden Statement at Finance Committee Markup of the Modernizing and Ensuring PBM Accountability Act (July 26, 2023), United States Senate Committee on Finance, available at <https://www.finance.senate.gov/chairmans-news/wyden-statement-at-finance-committee-markup-of-the-modernizing-and-ensuring-pbm-accountability-act> (last visited August 28, 2023).+(last+visited+August+28,+2023).>Google Scholar
Cohen, J., PBM Reform Legislation may be One Step Closer to Reality, but It’s Missing Two Key Components (May 13, 2023), Forbes, available at <https://www.forbes.com/sites/joshuacohen/2023/05/13/pbm-reform-legislation-may-be-one-step-closer-to-reality-but-its-missing-two-key-components/> (last visited August 28, 2023).+(last+visited+August+28,+2023).>Google Scholar
Dusetzina, S.B. et al., “Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending,” JAMA Internal Medicine 177 (2017): 1185–8.CrossRefGoogle ScholarPubMed